According to the user instructions from the manufacturer of OraQuick HIV self-test (HIVST) kits, individuals whose kits show one red band should be considered to be HIV-negative, no matter how weak the band is.
However, recent reports show potential for a second false weak band after storage, thereby creating confusion in the interpretation of results. In this study, we re-tested individuals whose results were initially non-reactive but changed to weak reactive results to determine their true HIV status.
This study was nested within a large, cluster-randomized HIVST trial implemented among pregnant women attending antenatal care and their male partners in central Uganda between July 2016 and February 2017. Ninety-five initially HIV-negative respondents were enrolled into this study, including 52 whose kits developed a second weak band while in storage and 43 whose kits were interpreted as HIV-positive by interviewers at the next follow-up interview.
Respondents were invited to return for repeat HIVST which was performed under the observation of a trained nurse counsellor. After HIVST, respondents underwent blood-based rapid HIV testing as per the national HIV testing algorithm (Determine (Abbot Laboratories), STAT-PAK (Chembio Diagnostic Systems Inc.) and Unigold (Trinity Biotech plc.) and dry blood spots were obtained for DNA/PCR testing. DNA/PCR was considered as the gold-standard HIV testing method.
4-Arm PEG-MA |
abx085177-10kDa1g |
Abbexa |
10 kDa; 1 g |
EUR 610.8 |
|
4-Arm PEG-MA |
abx085177-20kDa1g |
Abbexa |
20 kDa; 1 g |
EUR 610.8 |
|
4-Arm PEG-MA |
abx085177-20kDa5g |
Abbexa |
20 kDa; 5 g |
EUR 1228.8 |
|
4-Arm PEG-MA |
abx085177-5kDa1g |
Abbexa |
5 kDa; 1 g |
EUR 577.2 |
|
N-(m-PEG4)-N'-(PEG3-Mal)-Cy5 |
T18435-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
Description: N-(m-PEG4)-N'-(PEG3-Mal)-Cy5 |
N-(m-PEG4)-N'-(PEG3-Mal)-Cy5 |
T18435-1g |
TargetMol Chemicals |
1g |
Ask for price |
|
Description: N-(m-PEG4)-N'-(PEG3-Mal)-Cy5 |
N-(m-PEG4)-N'-(PEG3-Mal)-Cy5 |
T18435-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
Description: N-(m-PEG4)-N'-(PEG3-Mal)-Cy5 |
N-(m-PEG4)-N'-(PEG3-Mal)-Cy5 |
T18435-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
Description: N-(m-PEG4)-N'-(PEG3-Mal)-Cy5 |
N-(m-PEG4)-N'-(PEG3-Mal)-Cy5 |
T18435-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
Description: N-(m-PEG4)-N'-(PEG3-Mal)-Cy5 |
Cy3.5-PEG-Mal,2K |
FL077022-2K-500mg |
Biochempeg |
500mg |
EUR 652.8 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
Cy3.5-PEG-Mal,3.4K |
FL077022-3.4K-500mg |
Biochempeg |
500mg |
EUR 652.8 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
Cy3.5-PEG-Mal,5K |
FL077022-5K-500mg |
Biochempeg |
500mg |
EUR 652.8 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
Cy3.5-PEG-Mal |
abx085322-10kDa500mg |
Abbexa |
10 kDa; 500 mg |
EUR 961.2 |
|
Cy3.5-PEG-Mal |
abx085322-2kDa500mg |
Abbexa |
2 kDa; 500 mg |
EUR 961.2 |
|
Cy3.5-PEG-Mal |
abx085322-34kDa500mg |
Abbexa |
3.4 kDa; 500 mg |
EUR 961.2 |
|
Cy3.5-PEG-Mal |
abx085322-5kDa500mg |
Abbexa |
5 kDa; 500 mg |
EUR 961.2 |
|
PCL(12K)-PEG-Mal |
abx085326-10kDa500mg |
Abbexa |
10 kDa; 500 mg |
EUR 1144.8 |
|
PCL(12K)-PEG-Mal |
abx085326-2kDa500mg |
Abbexa |
2 kDa; 500 mg |
EUR 1144.8 |
|
PCL(12K)-PEG-Mal |
abx085326-5kDa500mg |
Abbexa |
5 kDa; 500 mg |
EUR 1144.8 |
|
PLGA(5K)-PEG-Mal |
abx085332-34kDa500mg |
Abbexa |
3.4 kDa; 500 mg |
EUR 1245.6 |
|
PLGA(50:50)(8K)-PEG-Mal |
abx085344-05kDa500mg |
Abbexa |
0.5 kDa; 500 mg |
EUR 1296 |
|
PLGA(50:50)(8K)-PEG-Mal |
abx085344-1kDa500mg |
Abbexa |
1 kDa; 500 mg |
EUR 1446 |
|
PLGA(50:50)(8K)-PEG-Mal |
abx085344-2kDa500mg |
Abbexa |
2 kDa; 500 mg |
EUR 1479.6 |
|
PLGA(50:50)(8K)-PEG-Mal |
abx085344-34kDa500mg |
Abbexa |
3.4 kDa; 500 mg |
EUR 1479.6 |
|
4-Arm PEG-Mal |
abx085089-10kDa1g |
Abbexa |
10 kDa; 1 g |
EUR 477.6 |
|
4-Arm PEG-Mal |
abx085089-20kDa1g |
Abbexa |
20 kDa; 1 g |
EUR 477.6 |
|
4-Arm PEG-Mal |
abx085089-20kDa5g |
Abbexa |
20 kDa; 5 g |
EUR 844.8 |
|
4-Arm PEG-Mal |
abx085089-5kDa1g |
Abbexa |
5 kDa; 1 g |
EUR 444 |
|
8-Arm PEG-Mal |
abx085119-10kDa1g |
Abbexa |
10 kDa; 1 g |
EUR 444 |
|
8-Arm PEG-Mal |
abx085119-20kDa1g |
Abbexa |
20 kDa; 1 g |
EUR 444 |
|
8-Arm PEG-Mal |
abx085119-20kDa5g |
Abbexa |
20 kDa; 5 g |
EUR 961.2 |
|
8-Arm PEG-Mal |
abx085119-40kDa1g |
Abbexa |
40 kDa; 1 g |
EUR 444 |
|
PCL(12K)-PEG-Mal,2K |
HE062022-2K-500mg |
Biochempeg |
500mg |
EUR 800.4 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PCL(12K)-PEG-Mal,5K |
HE062022-5K-500mg |
Biochempeg |
500mg |
EUR 800.4 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(5K)-PEG-MAL,2K |
HE085022-2K-500mg |
Biochempeg |
500mg |
EUR 873.6 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(5K)-PEG-MAL,3.4K |
HE085022-3.4K-500mg |
Biochempeg |
500mg |
EUR 873.6 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(5K)-PEG-MAL,5K |
HE085022-5K-500mg |
Biochempeg |
500mg |
EUR 873.6 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(50:50)?8K?-PEG-Mal,1K |
HE086022-1K-500mg |
Biochempeg |
500mg |
EUR 800.4 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(50:50)?8K?-PEG-Mal,2K |
HE086022-2K-500mg |
Biochempeg |
500mg |
EUR 770.4 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(50:50)?8K?-PEG-Mal,3.4K |
HE086022-3.4K-500mg |
Biochempeg |
500mg |
EUR 770.4 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(50:50)?8K?-PEG-Mal,500 |
HE086022-500-500mg |
Biochempeg |
500mg |
EUR 918 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(50:50)?8K?-PEG-Mal,5K |
HE086022-5K-500mg |
Biochempeg |
500mg |
EUR 770.4 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
4-Arm PEG-Mal |
abx085089-100l |
Abbexa |
100 µl |
EUR 300 |
4-Arm PEG-Mal |
abx085089-1ml |
Abbexa |
1 ml |
EUR 312.5 |
4-Arm PEG-Mal |
abx085089-200l |
Abbexa |
200 µl |
EUR 312.5 |
8-Arm PEG-Mal |
abx085119-100l |
Abbexa |
100 µl |
EUR 300 |
8-Arm PEG-Mal |
abx085119-1ml |
Abbexa |
1 ml |
EUR 300 |
8-Arm PEG-Mal |
abx085119-200l |
Abbexa |
200 µl |
EUR 300 |
Cy3.5-PEG-Mal |
abx085322-100l |
Abbexa |
100 µl |
EUR 662.5 |
Cy3.5-PEG-Mal |
abx085322-1ml |
Abbexa |
1 ml |
EUR 662.5 |
Cy3.5-PEG-Mal |
abx085322-200l |
Abbexa |
200 µl |
EUR 662.5 |
Cy3.5-PEG-Mal,10K |
FL077022-10K-500mg |
Biochempeg |
500mg |
EUR 652.8 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
Cy3.5-PEG-Mal,20K |
FL077022-20K-500mg |
Biochempeg |
500mg |
EUR 652.8 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PCL(12K)-PEG-Mal,10K |
HE062022-10K-500mg |
Biochempeg |
500mg |
EUR 800.4 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PCL(12K)-PEG-Mal,20K |
HE062022-20K-500mg |
Biochempeg |
500mg |
EUR 800.4 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(12K)-PEG-MAL,2K |
33-HE088022-2K |
Biochempeg |
-
Ask for price
-
Ask for price
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(12K)-PEG-MAL,3.4K |
33-HE088022-3.4K |
Biochempeg |
-
Ask for price
-
Ask for price
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(12K)-PEG-MAL,5K |
33-HE088022-5K |
Biochempeg |
-
Ask for price
-
Ask for price
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(18K)-PEG-MAL,3.4K |
33-HE118022-3.4K |
Biochempeg |
-
Ask for price
-
Ask for price
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PLGA(30K)-PEG-Mal |
abx085340-100l |
Abbexa |
100 µl |
EUR 625 |
PLGA(30K)-PEG-Mal |
abx085340-1ml |
Abbexa |
1 ml |
Ask for price |
PLGA(30K)-PEG-Mal |
abx085340-200l |
Abbexa |
200 µl |
EUR 1025 |
PEG3-methylamine |
T16457-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
Description: PEG3-methylamine |
PEG3-methylamine |
T16457-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
Description: PEG3-methylamine |
PEG3-methylamine |
T16457-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
Description: PEG3-methylamine |
PEG3-methylamine |
T16457-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
Description: PEG3-methylamine |
Anti-TACSTD2 (clone 7E6)-PEG6-MMAD ADC |
ADC-W-292 |
Creative Biolabs |
1mg |
Ask for price |
Description: This ADC product is comprised of an anti-TACSTD2 monoclonal antibody (clone 7E6) conjugated via a PEG6 linker to MMAD |
Anti-TACSTD2 (clone C16)-PEG6-MMAD ADC |
ADC-W-538 |
Creative Biolabs |
1mg |
Ask for price |
Description: This ADC product is comprised of an anti-TACSTD2 monoclonal antibody (clone C16) conjugated via a PEG6 linker to MMAD |
4-Arm PEG-Methacrylate |
abx085177-100l |
Abbexa |
100 µl |
EUR 362.5 |
4-Arm PEG-Methacrylate |
abx085177-1ml |
Abbexa |
1 ml |
EUR 362.5 |
4-Arm PEG-Methacrylate |
abx085177-200l |
Abbexa |
200 µl |
EUR 362.5 |
Anti-MUC1 (clone huC242)-PEG4Mal-DM1 ADC |
ADC-W-313 |
Creative Biolabs |
1mg |
Ask for price |
Description: This ADC product is comprised of an anti-MUC1 monoclonal antibody (clone huC242) conjugated via a PEG4Mal linker to a DM1 |
Anti-TNFRSF17 (clone 2A1)-PEG4-Mal-DM4 ADC |
ADC-W-121 |
Creative Biolabs |
1mg |
Ask for price |
Description: This ADC product is comprised of an anti-TNFRSF17 monoclonal antibody (clone 2A1) conjugated via a PEG4-Mal linker to DM4 |
Anti-TNFRSF17 (clone 1E1)-PEG4-Mal-DM4 ADC |
ADC-W-125 |
Creative Biolabs |
1mg |
Ask for price |
Description: This ADC product is comprised of an anti-TNFRSF17 monoclonal antibody (clone 1E1) conjugated via a PEG4-Mal linker to DM4 |
N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester) |
T16248-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
Description: N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester) |
N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester) |
T16248-1g |
TargetMol Chemicals |
1g |
Ask for price |
|
Description: N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester) |
N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester) |
T16248-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
Description: N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester) |
N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester) |
T16248-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
Description: N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester) |
N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester) |
T16248-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
Description: N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester) |
Polyethylene glycol monomethacrylate (PEGMA 200) |
16712-100 |
Polysciences Europe GmbH |
100g |
EUR 332 |
Description: 25736-86-1 |
Polyethylene glycol monomethacrylate (PEGMA 400) |
16713-100 |
Polysciences Europe GmbH |
100g |
EUR 111 |
Description: 25736-86-1 |
Polyethylene glycol monomethacrylate (PEGMA 440) |
24890-1000 |
Polysciences Europe GmbH |
1kg |
EUR 420 |
Description: 25736-86-1 |
AzoDye-3 PEG10 Azide |
2483-1mg |
AAT Bioquest |
1 mg |
EUR 148 |
|
Description: AzoDye-3 PEG 10 azide is an excellent building block for labeling alkyne-containing molecules. |
AzoDye-3 PEG10 Alkyne |
2485-1mg |
AAT Bioquest |
1 mg |
EUR 148 |
|
Description: AzoDye-3 PEG10 alkyne is an excellent building block for labeling azide-containing molecules. |
PEG3 (untagged)-Human paternally expressed 3 (PEG3) transcript variant 3 |
SC327712 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG3 (GFP-tagged) - Human paternally expressed 3 (PEG3), transcript variant 3 |
RG229077 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG3 (Myc-DDK-tagged)-Human paternally expressed 3 (PEG3), transcript variant 3 |
RC229077 |
Origene Technologies GmbH |
10 µg |
Ask for price |
JBScreen Classic 3 (PEG 4000+ based) |
M-CS-103L |
MiTeGen |
24 solutions |
EUR 249 |
Description: JBScreen Classic 3 (PEG 4000+ based) |
PEG10 3'UTR GFP Stable Cell Line |
TU067724 |
ABM |
1.0 ml |
EUR 5540.4 |
Peg10 3'UTR GFP Stable Cell Line |
TU166183 |
ABM |
1.0 ml |
Ask for price |
Peg12 3'UTR GFP Stable Cell Line |
TU166184 |
ABM |
1.0 ml |
Ask for price |
Peg10 3'UTR GFP Stable Cell Line |
TU266070 |
ABM |
1.0 ml |
Ask for price |
Peg12 3'UTR GFP Stable Cell Line |
TU266071 |
ABM |
1.0 ml |
Ask for price |
Peg10 3'UTR Luciferase Stable Cell Line |
TU116183 |
ABM |
1.0 ml |
Ask for price |
Peg12 3'UTR Luciferase Stable Cell Line |
TU116184 |
ABM |
1.0 ml |
Ask for price |
PEG10 3'UTR Luciferase Stable Cell Line |
TU017724 |
ABM |
1.0 ml |
EUR 5540.4 |
Peg10 3'UTR Luciferase Stable Cell Line |
TU216070 |
ABM |
1.0 ml |
Ask for price |
Peg12 3'UTR Luciferase Stable Cell Line |
TU216071 |
ABM |
1.0 ml |
Ask for price |
DOTA-(t-butyl)3-PEG5-azide |
T17846-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
Description: DOTA-(t-butyl)3-PEG5-azide |
DOTA-(t-butyl)3-PEG5-azide |
T17846-1g |
TargetMol Chemicals |
1g |
Ask for price |
|
Description: DOTA-(t-butyl)3-PEG5-azide |
DOTA-(t-butyl)3-PEG5-azide |
T17846-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
Description: DOTA-(t-butyl)3-PEG5-azide |
DOTA-(t-butyl)3-PEG5-azide |
T17846-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
Description: DOTA-(t-butyl)3-PEG5-azide |
DOTA-(t-butyl)3-PEG5-azide |
T17846-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
Description: DOTA-(t-butyl)3-PEG5-azide |
Peg12 sgRNA CRISPR Lentivector (Rat) (Target 3) |
K6370804 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Paternally Expressed 3 (PEG3) Antibody |
20-abx323448 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Paternally Expressed 3 (PEG3) Antibody |
abx331093-100ul |
Abbexa |
100 ul |
EUR 510 |
|
Paternally Expressed 3 (PEG3) Antibody |
20-abx013786 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 200 ug
- 300 µg
|
|
PEG10 sgRNA CRISPR Lentivector (Human) (Target 3) |
K1626704 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Peg12 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
K3769504 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Peg10 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
K4676404 |
ABM |
1.0 ug DNA |
EUR 184.8 |
PEG3 3'UTR GFP Stable Cell Line |
TU067722 |
ABM |
1.0 ml |
EUR 2799.6 |
Peg3 3'UTR GFP Stable Cell Line |
TU166185 |
ABM |
1.0 ml |
Ask for price |
JBScreen PEG/Salt 3 |
M-CS-143 |
MiTeGen |
24 solutions |
EUR 263 |
Description: JBScreen PEG/Salt 3 |
Absolute Mag™ PEG300 Magnetic Polystyrene Particles, 3 μm |
WHM-G394 |
Creative Diagnostics |
10 ml |
EUR 1160 |
Peg3 3'UTR Luciferase Stable Cell Line |
TU116185 |
ABM |
1.0 ml |
Ask for price |
PEG3 3'UTR Luciferase Stable Cell Line |
TU017722 |
ABM |
1.0 ml |
EUR 2799.6 |
3-D Life PEG-Link |
L50-1 |
Cellendes |
200 µl |
EUR 37 |
3-D Life PEG-Link |
L50-3 |
Cellendes |
3x 200 µl |
EUR 80 |
PEG3 sgRNA CRISPR Lentivector (Human) (Target 3) |
K1626504 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Peg3 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
K4341804 |
ABM |
1.0 ug DNA |
EUR 184.8 |
PEG3 (untagged)-Human paternally expressed 3 (PEG3) transcript variant 2 |
SC327323 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG3 (untagged)-Human paternally expressed 3 (PEG3) transcript variant 4 |
SC327324 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG3 (untagged)-Human paternally expressed 3 (PEG3) transcript variant 5 |
SC327713 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG3 (untagged)-Human paternally expressed 3 (PEG3), transcript variant 1 |
SC128281 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG3AS sgRNA CRISPR Lentivector (Human) (Target 3) |
K1626604 |
ABM |
1.0 ug DNA |
EUR 184.8 |
PEG3 (GFP-tagged) - Human paternally expressed 3 (PEG3), transcript variant 1 |
RG215328 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG3 (GFP-tagged) - Human paternally expressed 3 (PEG3), transcript variant 5 |
RG229078 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG3 (GFP-tagged) - Human paternally expressed 3 (PEG3), transcript variant 2 |
RG228688 |
Origene Technologies GmbH |
10 µg |
Ask for price |
PEG3 (GFP-tagged) - Human paternally expressed 3 (PEG3), transcript variant 4 |
RG228689 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Paternally-Expressed Gene 3 Protein (PEG3) Antibody |
abx013786-100l |
Abbexa |
100 µl |
EUR 43.75 |
Paternally-Expressed Gene 3 Protein (PEG3) Antibody |
abx323448-100g |
Abbexa |
100 µg |
EUR 250 |
Paternally-Expressed Gene 3 Protein (PEG3) Antibody |
abx323448-50g |
Abbexa |
50 µg |
EUR 187.5 |
Peg12 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
K6370808 |
ABM |
1.0 ug DNA |
EUR 200.4 |
DBCO-(PEG)3-VC-PAB-MMAE |
T17817-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
Description: DBCO-(PEG)3-VC-PAB-MMAE |
DBCO-(PEG)3-VC-PAB-MMAE |
T17817-1g |
TargetMol Chemicals |
1g |
Ask for price |
|
Description: DBCO-(PEG)3-VC-PAB-MMAE |
After repeat HIVST, 90 (94.7%) tested HIV-negative; 2 (2.1%) tested HIV-positive; and 3 (3.2%) had missing HIV test results. When respondents were subjected to blood-based rapid HIV testing, 97.9% (93/95) tested HIV-negative while 2.1% (2/95) tested HIV-positive.